Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly...
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is featured in an upcoming interview on the RedChip Small Stocks, Big Money(TM) show. During the program,...
Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon...
Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN , a multifaceted financial news and publishing company...
Nutriband (NASDAQ: NTRB, NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the...
Fentanyl, a potent opioid, poses a significant problem due to its potential for abuse with a high risk of overdose – even in small quantities. Nutriband (NASDAQ: NTRB) is advancing its AVERSA(TM) technology...
Nutriband (NASDAQ: NTRB), a company engaged in the development of abuse-deterrent pharmaceutical products, has entered into definitive securities purchase agreements. The agreements are for the purchase...
Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes...
/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END